First-line Therapy for metastatic hormone-sensitive Prostate Cancer   (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab   (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus   Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive   Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO

Titel:: First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO
Dokumenttyp:: Editorial Material
Autor(en):: Rexer, H.; Retz, M.; Hammerer, P.
Zeitschriftentitel:: Urologe A
Jahr:: 2021
Band / Volume:: 60
Heft / Issue:: 7
Seitenangaben Beitrag:: 987-988
Volltext / DOI:: doi:10.1007/s00120-021-01570-0
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/34255120
Print-ISSN:: 0340-2592
TUM Einrichtung:: Urologische Klinik und Poliklinik
BibTeX

Vorkommen: